12 Best Big Name Stocks to Invest in Now

Page 5 of 11

7. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holdings: 106

Eli Lilly and Company (NYSE:LLY) is a pharmaceutical giant known for its groundbreaking research and development in treatments for diabetes, cancer, and neurological disorders. The company’s recent success with its incretin portfolio, including tirzepatide and orforglipron, has positioned it for significant growth in the coming years.

Eli Lilly and Company (NYSE:LLY) is committed to fully realizing the potential of its incretin portfolio, which has shown tremendous promise in treating obesity and related metabolic disorders. The company is also investing heavily in the development of new formulations and indications, including the oral medication orforglipron, which is expected to launch in the near future. Additionally, Eli Lilly and Company (NYSE:LLY) is working to expand access to its existing medications, such as tirzepatide, through improved pricing and reimbursement strategies. The company has a strong pipeline of follow-on products, including the triple-acting retatrutide.

While the incretin portfolio is a key driver of growth for Eli Lilly and Company (NYSE:LLY), the company is also focused on diversifying its business through strategic investments in other therapeutic areas. Eli Lilly and Company (NYSE:LLY) has a strong presence in oncology, immunology, and neuroscience, and is investing in new technologies and partnerships to drive innovation in these areas. The company is also exploring opportunities in emerging fields such as gene therapy and regenerative medicine, with the goal of creating new treatment options for patients with serious diseases.

Page 5 of 11